Pharmaceuticals

  • Brexit’s Impact on Healthcare and Life Sciences

    Health and life sciences are heavily regulated sectors, which directly employ a significant proportion of the workforce across health and care delivery, pharmaceuticals, research and development, education, animal health and the many other issues covered by the sector. The sector drives a significant percentage of trade inside and outside the EU market and healthcare consumes,…

  • mHealth: Harnessing Growth and Innovation

    mHealth is changing the face of healthcare. While its potential is vast, the test for healthcare systems is to capture this value and translate it into concrete results. In our latest snapshot Kyra Obolensky and Lavinia Trehane from FTI Consulting’s healthcare team identify the challenges of building a robust and secure mHealth ecosystem and explore…

  • How to avoid slipping back to the ‘pre-penicillin era’

     This week the European Parliament adopted its own-initiative Report on Safer Healthcare in Europe: Improving Patient Safety and Fighting Antimicrobial Resistance. With this report MEPs are pointing to a looming global health crisis which requires urgent action on many fronts. In our latest snapshot Kyra Obolensky and Darren Kinsella from FTI Consulting’s healthcare team say…

  • What price medicine? A non-Brussels perspective on the EU’s role in shaping medicine prices.

    As part of our Healthy Thinking Series, on Tuesday 05 May FTI Consulting organised a debate on the role of the EU in the pricing and procurement of medicines. In order to broaden our perspective and move away from what can often be a technical debate we invited two speakers from outside the Brussels bubble,…

Back to top